3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Unknown
1
Terminated
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
4
Gastrointestinal
3
Breast
3
Lymphoid
2
Head & Neck
2
Gynecologic
2
Dermatologic
2
Thoracic
1
Plasma cell
1
Genitourinary
1
Conditions
Melanoma
5
Carcinoma, Non-Small-Cell Lung
4
Skin Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Sarcoma
2
Ovarian Neoplasms
2
Neoplasms
2
Lymphoma, T-Cell, Cutaneous
2
Colonic Neoplasms
2
Carcinoma, Merkel Cell
2
Zollinger-Ellison Syndrome
1
Waldenstrom Macroglobulinemia
1
Vipoma
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Sezary Syndrome
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Mycosis Fungoides
1
Interventions
Cyclophosphamide
16
pembrolizumab
14
Radiosurgery
7
Nivolumab
5
Celecoxib
5
poly ICLC
4
Radiation
4
Injections
4
Radiotherapy
3
Melphalan
3
Ipilimumab
3
Filgrastim
3
Etoposide
3
Docetaxel
3
Cryosurgery
3
Blood Specimen Collection
3
Biopsy
3
130-nm albumin-bound paclitaxel
3
trastuzumab deruxtecan
2
tislelizumab
2
talimogene laherparepvec
2
spartalizumab
2
fludarabine phosphate
2
fludarabine
2
durvalumab
2
cemiplimab
2
atezolizumab
2
aldesleukin
2
Transurethral Resection of Prostate
2
Therapeutics
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Sarcoma
×
Capecitabine
×
Dermatologic
×
Clear all
NCT03009058
2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2
Terminated
2 enrolled
7 charts
NCT03775525
2022-12-23
GEN602
Genzada Pharmaceuticals USA, Inc.
Phase 1
Unknown
127 enrolled